Publicaties
- Germonpré P, Janssens A, Van Moorter L, Verresen D, Galdermans D, Devogelaere R, Ottevaere H, Mentens Y, De Pooter C, Goor C. A Multicenter Phase II Trial Of Carboplatin And Gemcitabine Followed By Concurrent Chemoradiation In Patients With Unresectable Stage III Non-Small-Cell-Lung Cancer (NSCLC): FEV1 as Prognostic Marker. Am J Respir Crit Care Med 2008; vol 177: A311.
- Devogelaere R, Ottevaere H, Mentens Y, De Pooter C, Goor C. Multicenter Phase II Trial Of Carboplatin (Cb) And Gemcitabine (G) Followed By Concurrent Chemoradiation In Patients With Unresectable Stage III Non-Small-Cell-Lung Cancer (NSCLC): FEV1 as Prognostic Marker. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings Part I vol 26: 7558.
- Galdermans D., Driesen P., Bustin F., Lambrechts M., Deschepper K., Stappaerts I., Verresen D., Janssens A., Germonpré P. R. A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings Part I vol 26: 7594.
- Germonpré P, Janssens A, Galdermans D, Ortmanns P, Deschepper K, Devogelaere R, De Droogh E, De Pooter C, Goor C. A Randomized Multicenter Phase II ¶¶Òõ¶ÌÊÓƵ Of Concurrent Pemetrexed And Radiotherapy With Induction Or Adjuvant Cisplatin/Pemetrexed In Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2009, 4 suppl 1: S853.
- Germonpré P, Janssens A, Nowé V, Boeykens E, De Pooter C, Goor C. FEV1 as prognostic marker in stage III non-small cell (NSCLC) patients treated with chemoradiation: pooled analysis of two multicenter phase II trials. J Thorac Oncol 2010, 5 (suppl 7): S518.